We are live on ! Find out more

Roivant Sciences

ROIV

Market cap $27.1B

37.52 USD

+0.41

1.1%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

37.52

0.00

0%

1 day

1.1%

5 days

0.91%

1 month

2.79%

3 months

14.15%

6 months

36.34%

Year to date

71.09%

1 year

100%

5 years

372.54%

10 years

301.28%

About: Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Employees: 721

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 32.4%

Neutral 67.6%

Negative 0%

Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript

Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript

Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript

Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results

Roivant Sciences NASDAQ: ROIV reported positive Phase III results from its CLARITY-1 and CLARITY-2 studies evaluating brepocitinib, which the company referred to as Brepo, in noninfectious uveitis (NIU), an inflammatory eye disease that can result in vision loss.

Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq:ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis (NIU). Brepocitinib met the primary endpoint for both the CLARITY-1 and CLARITY-2 studies. Brepocitinib also achieved statistically significant and clinically meaningful benefit on all key secondary endpoints, including measurements of sustained steroid-free quiescence at Week 48, chorioretinal vascular leakage, resolution of macular edema and patient-reported visual functioning. These results were achieved despite a substantially more aggressive steroid taper than precedent NIU trials.

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

BASEL, Switzerland and LONDON and NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 9, 2026, to report its financial results for the second quarter ended September 30, 2026, and provide a business update.

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months

Roivant Sciences NASDAQ: ROIV CEO Matthew Gline outlined the company's priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant's IMVT-1402, and expansion of its pulmonary hypertension program.

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant's internal bar to continue development of IMVT-1402 in CLE IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies All other clinical development timelines remain on track DURHAM, N.C., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 (imeroprubart) for the treatment of cutaneous lupus erythematosus (CLE).

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant's internal bar to continue development of IMVT-1402 in CLE IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies All other clinical development timelines remain on track BASEL, Switzerland and LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced topline results from Period 1 of Immunovant's proof-of-concept trial evaluating IMVT-1402 (imeroprubart) for the treatment of cutaneous lupus erythematosus (CLE).

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

LISRAYA's recent approval gives ROIV a nice commercial foundation, while additional indications could turn brepocitinib into a broader immunology franchise. ROIV's pulmonary asset with mosliciguat is also promising. This candidate may be helpful for vascular resistance and walking distance improvements. I believe mosliciguat could over time become a valuable pulmonary franchise, but we still need to see how its subsequent Phase 3 plays out.

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

See News Rankings

Price charts implemented using Lightweight Charts™